In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis

Phytotherapy Research

Volumn 17, Issue 3, 2003, Pages 217-221

  Mahady, Gail B ^a   Pendland, Susan L ^a   Stoia, Adenia ^a   Chadwick, Lucas R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Berberine; Helicobacter pylori; Hydrastis canadensis; Sanguinaria canadensis; Sanguinarine

Indexed keywords

BENZOPHENANTHRIDINE DERIVATIVE; BERBINE DERIVATIVE; CHELERYTHRINE; HYDRASTINE; ISOQUINOLINE ALKALOID; METHANOL; PLANT EXTRACT; PROTOPINE; SANGUINARINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG IDENTIFICATION; DRUG SENSITIVITY; DRUG STRUCTURE; HELICOBACTER PYLORI; HYDRASTIS; HYDRASTIS CANADENSIS EXTRACT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANT ROOT; RHIZOME; SANGUINARIA CANADENSIS; STRUCTURE ANALYSIS;

ALKALOIDS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDRASTIS; ISOQUINOLINES; MICROBIAL SENSITIVITY TESTS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; SANGUINARIA;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER CANADENSIS; HELICOBACTER PYLORI; HYDRASTIS CANADENSIS; SANGUINARIA CANADENSIS;

EID: 0344406943     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1108     Document Type: Article

References (43)

1. Anderson LB. 1885. Sanguinaria canadensis. Therapeutic Gazette 3: 805-808.
2. Bae EA, Han MJ, Kim NJ, Kim DH. 1998. Anti-helicobacter pylori activity of herbal medicines. Biol Pharm Bull 21: 990-992.
3. Becci PJ, Schwartz H, Barnes HH, Southard GL. 1987. Shortterm toxicity studies of sanguinarine and two alkaloid extracts of Sanguinaria canadensis L. J Toxicol Environ Health 20: 199-208.
4. Breuer T, Malaty, HM, Graham DY. 1997. The epidemiology of H. pylori-associated gastroduodenal diseases. In The Immunobiology of H. pylori, Ernst PB, Michetti P, Smith PD (eds). Lippincott-Raven: Philadelphia, PA; 29-47.
5. D'Amico MI. 1950. Investigation of the presence of substances having antibiotic action in higher plants. Fitoterapia 21: 77-80.
6. Der Marderosian AH. 1977. Pharmacognosy: medicinal teasboon or bane. Drug Therapy 7: 178-186.
7. Doig P, Trust TJ. 1997. The molecular basis for H. pylori adherence and colonization. In The Immunobiology of H. pylori, Ernst PB, Michetti P, Smith PD (eds), Lippincott-Raven: Philadelphia, PA; 47-57.
8. Dore MP, Osato MS, Realdi G, et al. 1999. Amoxycillin tolerance in H. pylori. J Antimicrob Chemother 43: 47-53.
9. Fabry W, Okemo P, Ansorg R. 1996. Activity of East African medicinal plants against Helicobacter pylori, Chemotherapy 42:315-317.
10. Fedorak R, Archambault A, Flamm R, et al. 1997. Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: metronidazole, clarithromycin, and amoxicillin, Gasteroenterology 112: Abstract A115.
11. Frigo P, Lang C, Reisenberger K, et al. 1998. Hyperemesis gravidarum associated with Helicobacter pylori seropositivity. Obstet Gynecol 91: 615-617.
12. Gentry EJ, Jampani HB, Ali Keshavarz-Shokri et al. 1998. Antitubercular natural products: Berberine from the roots of commercial Hydrastis canadensis powder. Isolation of inactive 8-oxotetrahydrothalifendine, canadine, β-hydrastine, and two new quinic acid esters, hycandinic acid esters-1 and -2. J Nat Prod 61: 1187-1193.
13. Gerhard M, Lehn N, Boren T, et al. 1999. Clinical relevance of the Helicobacter pylori gene for blood-group antigenbinding adhesin. PNAS96: 12778-1283.
14. Goodwin CS. 1997. Helicobacter pylori gastritis, peptic ulcer, and gastric cancer: clinical and molecular aspects. Clin Infect Dis 25: 1017-1019.
15. Gottshall RY, Lucas EH, Lickfeldt A, Roberts JM. 1949. The occurrence of antibacterial substances active against Mycobacterium tuberculosis in seed plants. J Clin Invest 28: 920-923.
16. Graham DY. 1989. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem. Am J Gastroenterol 89: 469-472.
17. Graham DY. 1994. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Prevent Med 23: 712-716.
18. Graham DY, de Boer WA, Tygat GN. 1996. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 91: 1072-1076.
19. Harkrader RJ. 1990. The history, chemistry and pharmacokinetics of Sanguinaria extract. J Canadian Dent Assoc 56 (Suppl.): 7-12.
20. Hocking GM. 1977. Folk medicine practice in North Carolina and adjacent states. Quarterly J Crude Drug Res 15: 152-154.
21. Hu FL. 1993. Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease, Zhonghua Yi Xue Za Zhi 73:217-219.
22. Huwez FU, Thirlwell D, Cockayne A et al. 1998. Mastic gum kills Helicobacter pylori, NEJM 339: 1946-1947.
23. Ilver D, Arnquist A, Ogren J, et al. 1998. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279: 373-377.
24. Ingsdorfer K, Hjalmarsdottir MA, Sigurdsson A, et al. 1997. In vitro susceptibility of Helicobacter pylori to protolichesterinic acid from the lichen Cetraria islandica, Antimicrob Agents Chemother 41: 215-217.
25. Jonkers D. 1999. Antibacterial effect of garlic and omeprazole on Helicobacter pylori J Antimicrob. Chemother 43: 837-839.
26. Keller KA, Meyer DL. 1989. Reproductive and developmental toxicological evaluation of sanguinaria extract. J Clin Dent 1: 59-66.
27. Kuipers EJ, Appelmelk BJ. 1997. Helicobacter pylori and atrophic gastritis. Biomed Pharmacother 51: 150-155.
28. Lampe KF. 1992. Berberine. In Adverse Effects of Herbal Drugs, Volume I, De Smet PA (ed.), Springer-Verlag: Berlin; 97-104.
29. Mahady GB, Schilling AB, Beecher CWW. 1993. Sanguinaria canadensis L.: In vitro culture and production of benzophenanthridine alkaloids. In Biotechnology in Agriculture and Forestry Vol. 24, Bajaj YPS (ed.), Springer-Verlag: Berlin; 313-328.
30. Mahady GB, Beecher CWW. 1994. Elicitor-stimulated benzophenanthridine alkaloid biosynthesis in bloodroot suspension cultures is mediated by calcium. Phytochemistry 37: 415-419.
31. Mahady GB, Chadwick LR. 2001. Goldenseal (Hydrastis canadensis): Is there enough evidence to support safety and efficacy? Nutr Clin Care 4: 243-249.
32. Markus HS, Mendall MA. 1998. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psych 64: 104-107.
33. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edition; Approved standard. NCCLS document M7-A4, vol. 17, no. 2. National Committee for Clinical Laboratory Standards, Wayne, PA.
34. National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing; Ninth informational supplement. NCCLS document M100-S9, vol. 19, no. 1. National Committee for Clinical Laboratory Standards, Wayne, PA.
35. Salcedo, JA, Al-Kawas F. 1998. Treatment of Helicobacter pylori infection. Arch Intern Med 158: 842-851.
36. Scazzocchio F, Cometa MF, Palmery M. 1998. Antimicrobial activity of Hydrastis canadensis extract and its major isolated alkaloids. Fitoterapia 69: 58-59.
37. Sivam GP, Lampe JW, Ulness B, et al. 1997. Helicobacter pylori - In vitro susceptibility to garlic (Allium sativum) extract. Nutr Can 27: 118-121.
38. Sun D, Abraham SN, Beachey EH. 1988. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother 32: 1274-1277.
39. Sung JJY, Chung SCS, Ling TKW. 1996. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Dig Dis Sci 41: 453-457.
40. Tabak M, Armon R, Potasman I, Neeman I. 1996. In vitro inhibition of Helicobacter pylori by extracts of thyme. J Appl Bacteriol 80: 667-672.
41. Veninga L, Zaricor BR. 1976. Goldenseal. Ruka Publications: Santa Cruz, CA.
42. Walker C. 1990. Effects of sanguinarine and Sanguinaria extract on the microbiota associated with the oral cavity. J Canadian Dent Assoc 56 (Suppl.): 13-17.
43. Winterburn GW. 1885. Sanguinaria canadensis. Trans National Eclectic Medical Assoc 10: 381-401.